Teladoc Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Teladoc Health, Inc. on October 1, 2024, reporting events occurring on September 27, 2024. The filing addresses a significant change in executive leadership involving the Chief Operating Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On September 27, 2024, Michael Waters, Chief Operating Officer, resigned with good reason under his executive employment agreement. The resignation is linked to a change in the Company's executive reporting structure. His departure is effective as of the close of business on December 31, 2024.
Management Commentary and Contingencies
In connection with Mr. Waters' resignation, the Company has agreed to the following compensatory arrangements:
- Nine months of continued base salary.
- Up to nine months of premiums for continued medical, dental, or vision coverage pursuant to COBRA.
- Any earned but unpaid annual bonus for 2024.
- Accelerated vesting of all time-based equity awards granted prior to the Separation Date that are unvested and scheduled to vest within the nine months following the Separation Date.
- Continued eligibility to vest in performance-based awards if conditions are satisfied during the nine-month period.
These benefits are contingent upon Mr. Waters remaining an employee through the Separation Date, executing a separation and release agreement (including a release of claims), and adhering to 9-month post-termination non-compete and non-solicit obligations.
Key Facts for Investor Verification
- Confirm the effective date of Michael Waters' departure (December 31, 2024).
- Verify the specific details of the "change in executive reporting structure" cited as the reason for resignation.
- Assess the total financial impact of the accelerated equity vesting and continued salary payments on the Company's compensation expenses.
- Monitor for the appointment of a successor Chief Operating Officer.